Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine α4β2 Receptor Antagonist for the Treatment of Depression
作者:Ramakrishna Nirogi、Abdul Rasheed Mohammed、Anil K. Shinde、Srinivasa Rao Ravella、Narsimha Bogaraju、Ramkumar Subramanian、Venkat Reddy Mekala、Raghava Choudary Palacharla、Nageswararao Muddana、Jagadeesh Babu Thentu、Gopinadh Bhyrapuneni、Renny Abraham、Venkat Jasti
DOI:10.1021/acs.jmedchem.9b00790
日期:2020.3.26
guided by in vitro affinity at the α4β2 receptor in combination with selectivity against the α3β4 receptor, pharmacokinetic evaluation, and in vivo efficacy in a forced swim test resulted in identification of 3-(6-chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane hydrochloride (9h, SUVN-911) as a clinical candidate. Compound 9h is a potent α4β2 receptor ligand with a Ki value of 1.5 nM. It showed
在对α4β2受体的体外亲和力以及对α3β4受体的选择性,药代动力学评估以及在强制游泳试验中的体内功效的指导下,进行了一系列化学优化,从而鉴定出3-(6-氯吡啶-3-基氧基甲基)临床候选药物为-2-氮杂双环[3.1.0]己烷盐酸盐(9h,SUVN-911)。化合物9h是有效的α4β2受体配体,其Ki值为1.5nM。它显示出对神经节α3β4受体的结合亲和力> 10μM,除了对其他70个靶标表现出选择性。它具有口服生物利用度,并在大鼠中表现出良好的大脑渗透能力。大鼠中明显的抗抑郁活性和剂量依赖性受体占有率支持其在抑郁症治疗中的潜在治疗作用。它不影响运动活性,其剂量比其有效剂量高出几倍。它没有心血管和胃肠道副作用。成功的动物长期安全性研究以及健康人在安全性,耐受性和药代动力学方面的1期评估为进一步的发展铺平了道路。